Features include very common findings: Abnormal hair morphology and Abnormal blistering of the skin; and common findings: Milia. 10 total HPO annotations.

Biomarker and diagnostic research for acquired epidermolysis bullosa has been reported in the published literature.

No approved treatments are currently available for acquired epidermolysis bullosa. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for acquired epidermolysis bullosa, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for acquired epidermolysis bullosa. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Phenotype severity distribution: 2 very common features, 1 common feature.

Estimated prevalence: Unknown (Unknown prevalence).

3 clinical trials registered, 1 recruiting. Interventions under study include biologic therapy and drug therapy. Pipeline includes 1 PHASE4, 2 PHASE1. Research is primarily sponsored by academic and government institutions.

62 publications have been identified in PubMed for acquired epidermolysis bullosa. Research spans Review / Meta-Analysis (31%), Case Report / Case Series (21%), and Other (15%).